metformin hydrochloride 500 mg tablet + rosuvastatin 10 mg tablet + repaglinide 0.5 mg tablet + midazolam hydrochloride syrup + rezatapopt
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
TP53 Y220C Mutation
Conditions
TP53 Y220C Mutation, Advanced Solid Tumors
Trial Timeline
Feb 4, 2026 → Jan 1, 2028
NCT ID
NCT07372625About metformin hydrochloride 500 mg tablet + rosuvastatin 10 mg tablet + repaglinide 0.5 mg tablet + midazolam hydrochloride syrup + rezatapopt
metformin hydrochloride 500 mg tablet + rosuvastatin 10 mg tablet + repaglinide 0.5 mg tablet + midazolam hydrochloride syrup + rezatapopt is a phase 1 stage product being developed by PMV Pharmaceuticals for TP53 Y220C Mutation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07372625. Target conditions include TP53 Y220C Mutation, Advanced Solid Tumors.
Hype Score Breakdown
Clinical
6
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07372625 | Phase 1 | Recruiting |
Competing Products
1 competing product in TP53 Y220C Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HDM201 + ancillary treatment | Novartis | Phase 1 | 29 |